vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $199.5M, roughly 1.4× VIRTUS INVESTMENT PARTNERS, INC.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 3.6%, a 92.8% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -4.1%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -5.7%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
ACAD vs VRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $199.5M |
| Net Profit | $273.6M | $7.1M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 7.7% |
| Net Margin | 96.3% | 3.6% |
| Revenue YoY | 9.4% | -4.1% |
| Net Profit YoY | 90.3% | -78.1% |
| EPS (diluted) | $1.61 | $1.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $199.5M | ||
| Q4 25 | $284.0M | $208.0M | ||
| Q3 25 | $278.6M | $216.4M | ||
| Q2 25 | $264.6M | $210.5M | ||
| Q1 25 | $244.3M | $217.9M | ||
| Q4 24 | $259.6M | $233.5M | ||
| Q3 24 | $250.4M | $227.0M | ||
| Q2 24 | $242.0M | $224.4M |
| Q1 26 | — | $7.1M | ||
| Q4 25 | $273.6M | $33.9M | ||
| Q3 25 | $71.8M | $31.3M | ||
| Q2 25 | $26.7M | $42.7M | ||
| Q1 25 | $19.0M | $28.1M | ||
| Q4 24 | $143.7M | $39.5M | ||
| Q3 24 | $32.8M | $49.1M | ||
| Q2 24 | $33.4M | $26.0M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | — | 7.7% | ||
| Q4 25 | 6.1% | 19.1% | ||
| Q3 25 | 12.8% | 21.7% | ||
| Q2 25 | 12.2% | 21.5% | ||
| Q1 25 | 7.9% | 16.8% | ||
| Q4 24 | 59.1% | 21.7% | ||
| Q3 24 | 12.6% | 24.3% | ||
| Q2 24 | 12.6% | 19.7% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 96.3% | 16.3% | ||
| Q3 25 | 25.8% | 14.5% | ||
| Q2 25 | 10.1% | 20.3% | ||
| Q1 25 | 7.8% | 12.9% | ||
| Q4 24 | 55.4% | 16.9% | ||
| Q3 24 | 13.1% | 21.6% | ||
| Q2 24 | 13.8% | 11.6% |
| Q1 26 | — | $1.05 | ||
| Q4 25 | $1.61 | $5.15 | ||
| Q3 25 | $0.42 | $4.65 | ||
| Q2 25 | $0.16 | $6.12 | ||
| Q1 25 | $0.11 | $4.05 | ||
| Q4 24 | $0.86 | $4.65 | ||
| Q3 24 | $0.20 | $5.71 | ||
| Q2 24 | $0.20 | $2.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $136.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $93.6B |
| Total Assets | $1.6B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $136.6M | ||
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $390.0M | ||
| Q3 25 | — | $390.6M | ||
| Q2 25 | — | $231.3M | ||
| Q1 25 | — | $231.7M | ||
| Q4 24 | — | $232.1M | ||
| Q3 24 | — | $237.5M | ||
| Q2 24 | — | $247.6M |
| Q1 26 | — | $93.6B | ||
| Q4 25 | $1.2B | $934.0M | ||
| Q3 25 | $917.3M | $918.7M | ||
| Q2 25 | $822.4M | $896.4M | ||
| Q1 25 | $765.2M | $893.7M | ||
| Q4 24 | $732.8M | $897.5M | ||
| Q3 24 | $577.2M | $889.0M | ||
| Q2 24 | $516.7M | $868.7M |
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | $4.3B | ||
| Q3 25 | $1.3B | $3.9B | ||
| Q2 25 | $1.2B | $3.7B | ||
| Q1 25 | $1.1B | $3.7B | ||
| Q4 24 | $1.2B | $4.0B | ||
| Q3 24 | $976.9M | $3.6B | ||
| Q2 24 | $914.1M | $3.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 0.43× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.26× | ||
| Q4 24 | — | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $-67.2M | ||
| Q3 25 | $74.3M | $108.3M | ||
| Q2 25 | $64.0M | $75.8M | ||
| Q1 25 | $20.3M | $-3.8M | ||
| Q4 24 | $40.4M | $1.8M | ||
| Q3 24 | $63.2M | $69.1M | ||
| Q2 24 | $25.0M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-74.1M | ||
| Q3 25 | $73.9M | $106.9M | ||
| Q2 25 | — | $74.2M | ||
| Q1 25 | — | $-6.8M | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | $63.2M | $68.7M | ||
| Q2 24 | — | $68.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | -35.6% | ||
| Q3 25 | 26.5% | 49.4% | ||
| Q2 25 | — | 35.2% | ||
| Q1 25 | — | -3.1% | ||
| Q4 24 | — | -1.6% | ||
| Q3 24 | 25.2% | 30.3% | ||
| Q2 24 | — | 30.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.3% | ||
| Q3 25 | 0.1% | 0.7% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | — | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | -1.99× | ||
| Q3 25 | 1.03× | 3.45× | ||
| Q2 25 | 2.40× | 1.77× | ||
| Q1 25 | 1.07× | -0.13× | ||
| Q4 24 | 0.28× | 0.04× | ||
| Q3 24 | 1.93× | 1.41× | ||
| Q2 24 | 0.75× | 2.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
VRTS
| Investment management fees | $169.1M | 85% |
| Administration and shareholder service fees | $17.3M | 9% |
| Distribution and service fees | $11.6M | 6% |
